- Mutual Funds
- Nippon India Pharma Fund - Direct (Bonus)
Nippon India Pharma Fund - Direct (Bonus)
Sectoral / Thematic
- NAV 575.03 (-0.31%)
- Fund Size (Cr) ₹8139.57
- Expense Ratio 0.92
- Scheme Type Active Fund
-
Value Research
- Minimum investment ₹5000
- Minimum Additional Investment ₹1000
- Minimum SIP Investment -
- Minimum Withdrawal ₹100
-
Exit Load
1%
- Return Since Launch 19.75%
Basic Details
Sailesh Raj Bhan
BSE Healthcare TRI
OPEN
Lumpsum Returns
Note: Lumpsum Returns since Inception Date.
SIP Returns
Note: SIP Returns since Inception Date.
Tax Treatment
If sold after 1 year from purchase date, long term capital gain tax will be applicable. Current tax rate is 10%, if your total long term capital gain exceeds 1 lakh. Any cess/surcharge is not included.If sold before 1 year from purchase date, short term capital gain tax will be applicable. Current tax rate is 15%. Any cess/surcharge is not included in the 15%.
Mutual Funds Calculator
-
Investment Type
-
Monthly Investment
₹ -
Expected Returns Rate
% -
Time Period
yrs
Total of your Investment will be
₹ 0
Returns
-
Invested Amount
0
-
Estimated Returns
0
-
Select Scheme
-
Investment Type
-
Monthly Investment
₹ -
Time Period
Total of your Investment will be
₹ 0
Returns
-
Invested Amount
0
-
Estimated Returns
0
Risk Ratios
-
Standard Deviation
4.30% -
Beta
0.93% -
Sharpe Ratio
0.45% -
Treynor’s Ratio
0.34% -
Jension’s Alpha
2.11%
Asset Allocation
There is no Asset Allocation data.
Sector Allocation
There is no Sector Allocation data.
Top 10 stock holding in portfolio
Peer Comparison
- Scheme Name
- Value Research
- Asset Size (Cr)
- 1M
- 3M
- 6M
- 1Y
- 3Y
-
Nippon India Pharma Fund - Direct (Bonus)
- 8139.57
- 7.10%
- 18.86%
- 22.73%
- 51.46%
- 19.25%
-
HDFC Defence Fund - Direct (G)
- 3930.99
- 1.64%
- 15.54%
- 35.40%
- 84.19%
- -
-
HDFC Defence Fund - Direct (IDCW)
- 3930.99
- 1.64%
- 15.54%
- 35.40%
- 84.19%
- -
-
Invesco India PSU Equity Fund - Direct (G)
- 1663.11
- 1.68%
- 13.21%
- 18.98%
- 80.66%
- 39.46%
-
Invesco India PSU Equity Fund - Direct (IDCW)
- 1663.11
- 1.69%
- 13.23%
- 18.98%
- 80.63%
- 39.42%
-
ICICI Pru PSU Equity Fund - Direct (G)
- 2702.79
- 1.11%
- 13.52%
- 12.45%
- 79.07%
- -
News
-
Nippon India Mutual Fund announces change in Key Personnel
Nippon India Mutual Fund has announced that Mr. Chetan Desai has been appointed as an Independent Director on the Board of NLITL w.e.f. August 28, 2024.
Details of Mr. Chetan Desai
Age: 73 years
Designation: Independent Director
Qualification: Chartered Accountant
Powered by Capital Market - Live News
-
Nippon India MF launches Nifty 500 Equal Weight Index Fund
Nippon India Mutual Fund has introduced the Nippon India Nifty 500 Equal Weight Index Fund, a unique investment opportunity that provides equal exposure to each of the 500 stocks in the Nifty 500 Index.
The New Fund Offer (NFO) for the fund is open from August 21st to September 4th. The fund seeks to deliver returns that closely track the Nifty 500 Equal Weight Index.
Unlike traditional market-cap weighted indices, which give larger companies a greater influence, the Nifty 500 Equal Weight Index assigns the same weight to every constituent stock, regardless of its size. This approach aims to reduce concentration risk and offer a more diversified portfolio.
The index is divided into three segments: Large Cap (20%), Mid Cap (30%), and Small Cap (50%). The higher allocation to Mid and Small Cap stocks can potentially capture additional returns during periods of favorable market conditions.
The fund's constituents will be reviewed and adjusted twice a year, typically in March and September, to ensure alignment with the underlying Nifty 500 index. To maintain equal weighting, the fund's individual stock positions will be rebalanced quarterly (March, June, September, and December).
The Nifty 500 Equal Weight TRI index has demonstrated superior performance compared to its market-cap weighted counterpart, the Nifty 500 TRI. Over the past five years, the equal weight index achieved a CAGR of 30.6%, while the Nifty 500 TRI returned 22.3%. Similarly, over the past three years, the equal weight index delivered a CAGR of 25.9%, outperforming the Nifty 500 TRI's 21% return.
Powered by Capital Market - Live News
-
Nippon India MF announces change in Fund Manager of the following schemes
Nippon India Mutual Fund has announced change in Fund Managers of the following schemes with effect from: 19 August 2024
Change in Fund Managers of the Schemes:
Scheme Name Fund Manager (Existing) Revised Fund Manager(s) Nippon India Large Cap Fund Sailesh Raj Bhan
Ashutosh Bhargava (Co-Fund Manager)Sailesh Raj Bhan
Bhavik Dave (Assistant Fund manager)Nippon India Focused Equity Fund Vinay Sharma Vinay Sharma
Rishit Parikh (Assistant Fund manager)Nippon India ELSS Tax Saver Fund Rupesh Patel
Ashutosh Bhargava (Co-fund manager)Rupesh Patel
Ritesh Rathod (Co-fund manager)Nippon India Power & Infra Fund Sanjay Doshi Rahul Modi Nippon India Innovation Fund Vinay Sharma Vinay Sharma
Rishit Parikh (Co-fund manager)Powered by Capital Market - Live News
Fund House Details & Investment Objective
-
Date of Incorporation
01-Jan-2013
-
Total AUM (Cr)
₹8647.95
Nippon India Pharma Fund - Direct (Bonus) is an Sectoral / Thematic-oriented fund from the renowned AMC, Nippon India Mutual Fund. Launched in Jan 2013, this fund is managed by Sailesh Raj Bhan. With assets under management (AUM) worth ₹8647.95 (Cr), as of 06-Sep-2024, Nippon India Pharma Fund - Direct (Bonus) is categorized as a Sectoral / Thematic within its segment. The fund has generated a return of 19.75% since its launch.
The current NAV of Nippon India Pharma Fund - Direct (Bonus) is ₹575.03, as on 06-Sep-2024. The fund’s benchmark index is BSE Healthcare TRI. You can invest in Nippon India Pharma Fund - Direct (Bonus) via both lumpsum and SIP modes. The minimum SIP amount in the fund is - while the minimum lumpsum investment is ₹5000.
Being an open-ended fund, you can exit the fund anytime subject to applicable exit loads:
1% if redeemed or switchd out on or efore completion of 1 Months from the date of allotment of units. NIl if redeemed or switched out after the completion of 1 Months from the date of allotment of units.
The fund has generated 19.25% and 30.83% CAGR in the last 3 and 5 years respectively.
The fund aims to provide long-term capital appreciation and growth, by investing in a mix of financial instruments 97.41% in Equity, 2.67% in Debt and -0.08% in cash and cash equivalents
The top 5 sectors the fund invests in are: 78.72% in Pharmaceuticals & Biotech, 17.15% in Healthcare Services, 2.57% in Retailing, 1.51% in Debt and 0.05% in Cash & Others.
FAQs on Nippon India Pharma Fund - Direct (Bonus)
Nippon India Pharma Fund - Direct (Bonus) is a popular fund in the Sectoral / Thematic segment. The fund has generated a return of 19.75% since inception. Looking to invest in Nippon India Pharma Fund - Direct (Bonus)? How about earning 1% extra return? All this is possible with m.Stock! Investing in Nippon India Pharma Fund - Direct (Bonus) is super easy and convenient with m.Stock. Here’s how you can begin:
- Login to your m.Stock account. If you do not have an account, open m.Stock Demat account and enjoy 1% extra returns plus Zero Brokerage across products for life.
- In the ‘Menu’ section, under ‘Products’, select ‘Mutual Funds’ .
- In the search bar, enter the fund name, in this case, Nippon India Pharma Fund - Direct (Bonus)
- On the top right corner you’ll see two options – Lumpsum and SIP. You can choose either based on your risk appetite and available investible corpus.
- If you choose to invest a Lumpsum: Enter amount, select payment mode (UPI or Netbanking), and click on ‘invest a lumpsum’. Make the payment and your lumpsum investment is complete.
- If you choose the SIP route, then enter SIP amount, SIP date, and set up ‘Autopay’ facility.
So, why wait? Invest in Nippon India Pharma Fund - Direct (Bonus) today and reap the benefits of this Sectoral / Thematic fund!
In the short term, i.e., 1 year, Nippon India Pharma Fund - Direct (Bonus) has generated annualised return of 51.46%. In the long-term, the fund has generated 19.25% and 30.83% in 3 and 5 years respectively. Since its inception, the fund has generated 19.75% returns.
The expense ratio of Nippon India Pharma Fund - Direct (Bonus) Direct Growth is 0.92%. Expense ratio is the fees payable by investors of the scheme towards management, research and overall upkeep of the fund. The higher the expense ratio, the lower is the in-hand return for the investor. Expense ratio for direct plans is lower than regular plans, making them ideal for investors.
The Assets Under Management (AUM) of Nippon India Pharma Fund - Direct (Bonus) is ₹8647.95 (Cr) as of 06 September 2024. AUM shows the fund’s popularity and is often indicative of fund strength.
Redeeming or selling units of Nippon India Pharma Fund - Direct (Bonus) is relatively simple. But before you redeem, ensure that the fund has completed the minimum lock-in period else you will be charged an exit load.
To redeem from Nippon India Pharma Fund - Direct (Bonus):
- Login to your m.Stock account
- In portfolio, your mutual fund investments will be visible under ‘MF’
- Select the fund you wish to redeem from (in this case Nippon India Pharma Fund - Direct (Bonus)).
- Click on ‘Redeem’ button
- You have 2 options – redeem by units and redeem by value (you can only redeem free units)
- Select units to be redeemed and click on submit.
- Redemption value will be credited to your account in 2-3 working days (as per timelines set by SEBI).
Yes, you can invest both lumpsum and SIP in Nippon India Pharma Fund - Direct (Bonus). Minimum lumpsum investment Nippon India Pharma Fund - Direct (Bonus) is ₹5000 and minimum SIP amount is -. Lumpsum option is ideal for investors with higher investible corpus and market experience. SIP option is recommended for retail investors who do not have the time or expertise to time the market.
The latest NAV (Net Asset Value) of Nippon India Pharma Fund - Direct (Bonus) is ₹575.03 as on 06 September 2024.
The 5 biggest stock holdings of Nippon India Pharma Fund - Direct (Bonus) are:
Sun Pharma.Inds. (13.81%), Lupin (8.3%), Divi's Lab. (7.96%), Cipla (5.93%), Dr Reddy's Labs (5.69%)
A majority of Nippon India Pharma Fund - Direct (Bonus) 's AUM worth ₹8647.95 (Cr) is invested in these 3 top sectors:
- Pharmaceuticals & Biotech: 78.72%
- Healthcare Services: 17.15%
- Retailing: 2.57%
Power your investments with our smart trading platforms
For a powerful, stable and secure experience,
download m.Stock App & set up your lifetime Zero brokerage account @ one-time fee of ₹999
-
Scan QR code to download
- OR
-
Enter number to get app link
+91
